Momepax (Mometasone Furoate)

Mometasone furoate, the active ingredient in Momepax, is a corticosteroid presented as a nasal spray for nasal administration. It is indicated for the treatment of allergic rhinitis, including seasonal and perennial forms, in patients requiring local anti‑inflammatory therapy. By targeting nasal mucosal inflammation, it helps relieve congestion, sneezing and itching associated with allergic triggers.

GNH USA supplies Momepax as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU GMP standards and providing the product to hospitals, pharmacies and clinics worldwide through reliable logistics and regulatory support.

Momepax, an intranasal corticosteroid, acts on the inflammatory pathway of the nasal mucosa to control allergic rhinitis and related nasal symptoms. Allergic rhinitis: reduces nasal congestion, sneezing, itching and rhinorrhea, improving overall nasal airflow and comfort. Seasonal allergic rhinitis: provides symptom relief during pollen seasons by decreasing mucosal edema and hypersecretion, leading to fewer episodes of sneezing and runny nose. Perennial allergic rhinitis: maintains nasal patency and comfort throughout the year by suppressing chronic inflammation, reducing daily nasal discharge and irritation.

Momepax may cause local and systemic adverse reactions, most of which are mild and reversible. Common Side Effects: - Nasal irritation or burning sensation: mild discomfort that usually resolves with continued use. - Epistaxis (nosebleeds): occasional bleeding from the nasal mucosa. - Headache: transient headache reported by some users. - Altered taste or throat irritation: temporary change in taste perception or mild throat soreness. Serious or Rare Side Effects: - Adrenal suppression with prolonged high‑dose use: may affect cortisol production and require monitoring. - Cataracts or glaucoma development: long‑term use can increase intra‑ocular pressure. - Severe allergic reaction such as anaphylaxis: rare but requires immediate medical attention.

When using Momepax, certain precautions should be observed to ensure safety and effectiveness. - Follow prescription: use the spray exactly as directed by the healthcare professional. - Avoid use during active nasal infection: postpone treatment until infection resolves. - Use with caution in children: monitor for growth suppression with long‑term therapy. - Monitor for systemic corticosteroid effects: watch for signs such as unusual fatigue or bruising. - Do not discontinue abruptly: taper the dose if long‑term therapy is stopped. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Momepax may interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure to mometasone. - Systemic corticosteroids: additive immunosuppressive effects and risk of adrenal suppression. - Ritonavir: potent inhibition of metabolism leading to higher local concentrations. Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., fluconazole): may modestly raise mometasone levels. - Anticonvulsants (e.g., phenytoin, carbamazepine): may reduce efficacy by inducing metabolism. - St. John’s wort: possible reduction in drug exposure through enzyme induction. - Diuretics (e.g., furosemide): may enhance nasal mucosal dryness.